of to commercial and hospital progress the Thanks, according settings both NUZYRA Evan. plan. The in community to launch continues
the in evidenced growth trajectory. commercial NUZYRA's graph year-over-year the net prior over right, as in revenue seen in has on year. NUZYRA's sales as resulted demonstrate performance quarter continues impressive the core same increase As upward earlier, to in growth an business noted trailing in XX-month Evan XX% the disciplined execution the by
As shown core quarter by in indicator trailing prior Slide the over same growth a continued increased long-term XX%. XX% in These of the future leading year, on the with of demand, third maintain the confidence XX-month gross growth sales our quarter XX, our data business. growth commercial of
all is represents This difference specialty and reporting sales use from As brief the the by reminder, driven accounts to our commercial is timing and gross channel, metric our fluctuations hospitals orders a as issue, our towards net The inventory between discounts pharmacy fulfilled we a for period. progress well throughout the partners demand determine community. as in goals. key gross-to-net associated distribution by prescriptions gross the and demand current all
our As QX, Slide antibiotic from of both IV can segments and oral growth launches. growth the you community NUZYRA's trajectory XX, is see recent saw in In other hospital more noticeably than business, successful demand.
this to NUZYRA it had However, business the slower grow, at a so anticipated. year, continued while the third specifically did in of pace Hospital quarter than we
there have impacting residual the of hospital to in in While volume be the overall the environment that system, reduced continues overall, there hospital the patients material overall pandemic effects utilization. of improvements antibiotic have been
resumed in recent certain report for representatives that pleased In sales more experiencing activities, physical received restrictions some numerous our reviews. successful addition, to In am to systems. we normal are we've hospital that the access formulary still I have hospitals
team of these to activities, sales working Our results coming now in hospitals expect pull-through and efforts over see on the are we the these quarters.
complicating care physicians. patients pulmonologists continues have of Our positions that on a care both and to discharge resistant and ID oral or suspected from also critical the appreciated hospital hospital focus to is value be for pathogens The in comorbidity. to with NUZYRA's known home formulation the patients by expedite who
hospital-acquired to resistant realized shortened by pathogen. infection risk to stay system, care pick cost patients also the up addition reduces savings with In another yet health for the bacterial of the length a a
the with performance prior have suggest expansion our in Early second liaisons promised, prescription community. now wave working performing data representatives, with specialty science expansion that number setting our of plan is into in now As covered complete. indicators sales these an in territories XXXX. approximately medical Paratek the to and and activity representatives new primary included We care consistent care. the primary XX in increase are community representatives This of
NUZYRA in Our resulted in community investment the this has accelerating demand QX prescription as in continued seen slide. on
is DOTs averaging representatives by increased of therapy community-based to the other recent XX% outpacing remain As community XX% the therapy clearly community-focused by oral sales of by on exceed the XXXX. to quarter. end end generated generated track of September, days more of by for Prescription NUZYRA's days third growth the a performance representatives The hospital-based the revenue and prescription to Rx continues key driver a be of their share launches. IV result, team of has the
revenue and to medical the We believe long-term success the of NUZYRA's that support yield sales will commercial growth. performance continue expansion community for
as to with out the home patients drug-resistant with is and primary community-based renal on skin have care diabetes. or hospital, such or physicians keeping NUZYRA proposition those podiatrists, the focus pneumonia infections suspected a patients number in a for at a value enabling impairment dermatologists. of comorbidity treatment targeting of oral Our using both by NUZYRA's known significant pathogen and select also is who team prescribing and concentrate
often symptoms a of in for will is major time track the have reporting year. you you leading season. This those that noticed a of serves as tick indicator substantial a that numbers, also flu For CDC of this flu-like up pneumonia
includes high-value continues to into significant. prepared least pathogen if this a This suspected physicians a this of on have with the significant opportunity capitalize pneumonia indicator our data i.e., patient pneumonia as identifying sales at these based one resistant their comorbidity. to patient have We this physicians our historical or NUZYRA developing and relationships and known something on trends more quinolone with use early team that many signifies follow types,
serious now with the that, our who building new remains and with establishing lives saving every treating always, and like trialists turn and are each usage to repeat objective and over call trust day. gaining credibility awareness in community-acquired As infections I'd to And and physicians overall by Randy.
